Published online Dec 16, 2021. doi: 10.4253/wjge.v13.i12.593
Peer-review started: March 12, 2021
First decision: October 17, 2021
Revised: October 19, 2021
Accepted: November 26, 2021
Article in press: November 26, 2021
Published online: December 16, 2021
Processing time: 276 Days and 8.4 Hours
Composite intestinal adenoma-microcarcinoid (CIAM) is a rare intestinal lesion consisting of conventional adenoma and small, well differentiated carcinoid [microcarcinoid (MC)] at its base. The incidence of CIAM is 3.8% in surgically resected colorectal polyps. While its pathogenesis is unknown, studies support the role of Wnt/β-catenin pathway in the tumorigenesis of CIAM. CIAMs have been primarily reported in the colon wherein they present as polyps with well-defined margins, similar to conventional adenomatous polyps. MC is usually found in adenomatous polyps with high-risk features such as large size, villous architecture, or high grade dysplasia. Histologically, the MC component is often multifocal and spans 3.9 to 5.8 millimeters in size. MC is usually confined within the mucosa but occasional CIAM cases with MC extending to the submucosa have been reported. MC of CIAM demonstrates bland cytology and inconspicuous proliferative activity. The lesional cells are positive for synaptophysin and 60% to 100% of cases show nuclear β-catenin positivity. MC poses a diagnostic challenge with its morphologic and immunohistochemical resemblance to both benign and malignant lesions, including squamous morules/metaplasia, adenocarcinoma, squamous cell carcinoma, sporadic neuroendocrine tumor and goblet cell adenocarcinoma. CIAM is an indolent lesion with a favorable outcome. Complete removal by polypectomy is considered curative. Awareness and recognition of this rare entity will help arrive at correct diagnosis and improve patient care. Currently, CIAM is not recognized as a subtype of mixed neuroendocrine-non-neuroendocrine neoplasm by WHO.
Core Tip: Composite intestinal adenoma-microcarcinoid (CIAM) is a rare intestinal lesion consisting of adenoma and well differentiated microcarcinoid components. While it is a form of mixed neoplasm with both neuroendocrine and non-neuroendocrine elements, CIAM is currently not recognized as a distinct subtype of mixed neoplasm by WHO. It is found incidentally during the pathologic examination of adenomatous polyps. Altered Wnt/β-catenin pathway appears to play a role in its pathogenesis. Other benign and malignant lesions need to be distinguished from CIAM given differing therapeutic implications. CIAM is an indolent disease with a favorable outcome.